October 18, 2006
View Full PaperOutcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial
Structured PICO
Does a valsartan-based regimen compared to an amlodipine-based regimen reduce the composite cardiac endpoint in subgroups of hypertensive patients?
P
Population
Hypertensive patients (subgroups from the VALUE trial cohort)
I
Intervention
Valsartan-based treatment regimen
C
Comparator
Amlodipine-based treatment regimen
O
Outcome
Composite cardiac endpointcomposite
Valsartan and amlodipine have similar effects on composite cardiac endpoints in hypertensive patients, though sex-specific differences in efficacy and heart failure prevention may exist.
Abstract
As in the whole VALUE cohort, in no subgroup of patients were there differences in the incidence of the composite cardiac endpoint with valsartan and amlodipine-based treatments, despite a greater blood pressure decrease in the amlodipine group. The only exception was sex, in which the amlodipine-based regimen was more effective than valsartan in women, but not in men, whereas the valsartan regimen was more effective in preventing cardiac failure in men than in women.